Clinical significance of interferon lambda-3 (IFNλ3)/interleukin 28B (IL28B) in systemic lupus erythematosus patients

Background: Inappropriate and excessive activation of type I interferon (IFN) system is a key feature of systemic lupus erythematosus (SLE), and its targeting has led to important achievements in the development of novel drugs for SLE. Aim of the work: To evaluate the serum levels of interferon lamb...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Fatma H. Abdelraouf, Manal E.S. Ramadan, Dina O. Abdulazim, AliGenena, Heba M. Selim
Formato:	article
Lenguaje:	EN
Publicado:	Elsevier 2022
Materias:	Interferon Lambda IL28B IFNλ3 Systemic lupus erythematosus SLEDAI Immunologic diseases. Allergy RC581-607
Acceso en línea:	https://doaj.org/article/1b7854bf86d5419fa149cc68dd2fb747
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:1b7854bf86d5419fa149cc68dd2fb747
record_format	dspace
spelling	oai:doaj.org-article:1b7854bf86d5419fa149cc68dd2fb7472021-11-12T04:27:01ZClinical significance of interferon lambda-3 (IFNλ3)/interleukin 28B (IL28B) in systemic lupus erythematosus patients1110-116410.1016/j.ejr.2021.10.004https://doaj.org/article/1b7854bf86d5419fa149cc68dd2fb7472022-04-01T00:00:00Zhttp://www.sciencedirect.com/science/article/pii/S1110116421000910https://doaj.org/toc/1110-1164Background: Inappropriate and excessive activation of type I interferon (IFN) system is a key feature of systemic lupus erythematosus (SLE), and its targeting has led to important achievements in the development of novel drugs for SLE. Aim of the work: To evaluate the serum levels of interferon lambda IFNλ3 (IL28B) in Egyptian patients with SLE and investigate its potential relation with different clinical and laboratory parameters. Patients and methods: The study included 40 SLE patients and 40 controls. The SLE disease activity index (SLEDAI) was assessed. The measurement of serum levels of IFNλ3 was performed in all participants using enzyme linked immunosorbent assay (ELISA). Results: The mean age of the patients was 26.8 ± 7.8 years with disease duration 5.1 ± 4.5 years and they were 35 females and 5 males. The serum levels of IFNλ3 were significantly higher in SLE patients (9.7 ± 12.47 pg/mL) compared to the control (5.13 ± 1.63 pg/mL)(p = 0.02). Significant correlations were observed between serum IFNλ3 and serositis (r = 0.35,p = 0.03), C3 consumption (r −0.33, p = 0.04) and SLEDAI (r 0.34, p = 0.03). On multivariate regression analysis, serositis and SLEDAI (but not C3) were significant independent predictors of IFNλ3 levels (β = 0.08, p = 0.037 and β = 0.06, p = 0.014 respectively). Conclusion: The results support a possible role of IFNλ3/IL28B in the immunopathogenesis of SLE. The significant association of serum IFNλ3 with disease activity highlights the utility of IFNλ3 as a novel biomarker for monitoring disease activity and predicting severity in SLE. Further studies on IFNλ3 in SLE could be promising in the development of personalized therapy for lupus patients.Fatma H. AbdelraoufManal E.S. RamadanDina O. Abdulazim AliGenenaHeba M. SelimElsevierarticleInterferon LambdaIL28BIFNλ3Systemic lupus erythematosusSLEDAIImmunologic diseases. AllergyRC581-607ENEgyptian Rheumatologist, Vol 44, Iss 2, Pp 121-125 (2022)
institution	DOAJ
collection	DOAJ
language	EN
topic	Interferon Lambda IL28B IFNλ3 Systemic lupus erythematosus SLEDAI Immunologic diseases. Allergy RC581-607
spellingShingle	Interferon Lambda IL28B IFNλ3 Systemic lupus erythematosus SLEDAI Immunologic diseases. Allergy RC581-607 Fatma H. Abdelraouf Manal E.S. Ramadan Dina O. Abdulazim AliGenena Heba M. Selim Clinical significance of interferon lambda-3 (IFNλ3)/interleukin 28B (IL28B) in systemic lupus erythematosus patients
description	Background: Inappropriate and excessive activation of type I interferon (IFN) system is a key feature of systemic lupus erythematosus (SLE), and its targeting has led to important achievements in the development of novel drugs for SLE. Aim of the work: To evaluate the serum levels of interferon lambda IFNλ3 (IL28B) in Egyptian patients with SLE and investigate its potential relation with different clinical and laboratory parameters. Patients and methods: The study included 40 SLE patients and 40 controls. The SLE disease activity index (SLEDAI) was assessed. The measurement of serum levels of IFNλ3 was performed in all participants using enzyme linked immunosorbent assay (ELISA). Results: The mean age of the patients was 26.8 ± 7.8 years with disease duration 5.1 ± 4.5 years and they were 35 females and 5 males. The serum levels of IFNλ3 were significantly higher in SLE patients (9.7 ± 12.47 pg/mL) compared to the control (5.13 ± 1.63 pg/mL)(p = 0.02). Significant correlations were observed between serum IFNλ3 and serositis (r = 0.35,p = 0.03), C3 consumption (r −0.33, p = 0.04) and SLEDAI (r 0.34, p = 0.03). On multivariate regression analysis, serositis and SLEDAI (but not C3) were significant independent predictors of IFNλ3 levels (β = 0.08, p = 0.037 and β = 0.06, p = 0.014 respectively). Conclusion: The results support a possible role of IFNλ3/IL28B in the immunopathogenesis of SLE. The significant association of serum IFNλ3 with disease activity highlights the utility of IFNλ3 as a novel biomarker for monitoring disease activity and predicting severity in SLE. Further studies on IFNλ3 in SLE could be promising in the development of personalized therapy for lupus patients.
format	article
author	Fatma H. Abdelraouf Manal E.S. Ramadan Dina O. Abdulazim AliGenena Heba M. Selim
author_facet	Fatma H. Abdelraouf Manal E.S. Ramadan Dina O. Abdulazim AliGenena Heba M. Selim
author_sort	Fatma H. Abdelraouf
title	Clinical significance of interferon lambda-3 (IFNλ3)/interleukin 28B (IL28B) in systemic lupus erythematosus patients
title_short	Clinical significance of interferon lambda-3 (IFNλ3)/interleukin 28B (IL28B) in systemic lupus erythematosus patients
title_full	Clinical significance of interferon lambda-3 (IFNλ3)/interleukin 28B (IL28B) in systemic lupus erythematosus patients
title_fullStr	Clinical significance of interferon lambda-3 (IFNλ3)/interleukin 28B (IL28B) in systemic lupus erythematosus patients
title_full_unstemmed	Clinical significance of interferon lambda-3 (IFNλ3)/interleukin 28B (IL28B) in systemic lupus erythematosus patients
title_sort	clinical significance of interferon lambda-3 (ifnλ3)/interleukin 28b (il28b) in systemic lupus erythematosus patients
publisher	Elsevier
publishDate	2022
url	https://doaj.org/article/1b7854bf86d5419fa149cc68dd2fb747
work_keys_str_mv	AT fatmahabdelraouf clinicalsignificanceofinterferonlambda3ifnl3interleukin28bil28binsystemiclupuserythematosuspatients AT manalesramadan clinicalsignificanceofinterferonlambda3ifnl3interleukin28bil28binsystemiclupuserythematosuspatients AT dinaoabdulazim clinicalsignificanceofinterferonlambda3ifnl3interleukin28bil28binsystemiclupuserythematosuspatients AT aligenena clinicalsignificanceofinterferonlambda3ifnl3interleukin28bil28binsystemiclupuserythematosuspatients AT hebamselim clinicalsignificanceofinterferonlambda3ifnl3interleukin28bil28binsystemiclupuserythematosuspatients
_version_	1718431275783553024

Clinical significance of interferon lambda-3 (IFNλ3)/interleukin 28B (IL28B) in systemic lupus erythematosus patients

Ejemplares similares